Bio-Dome wound interface dressings superior than GranuFoam

NewsGuard 100/100 Score

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new in vitro study results. The Engenex® Negative Pressure Wound Therapy (NPWT) system's Bio-Dome™ wound interface showed superior tensile strength and lower simulated bioadhesion when compared with GranuFoam™ (polyurethane foam). This study was conducted by employees of ConvaTec's Global Development Center and was presented at The Annual Fall Symposium on Advanced Wound Care in Anaheim, California.

In addition to the superior tensile strength and lower simulated bioadhesion, the laboratory tests also showed that the Bio-Dome™ wound interface provided broader contours of microstrain when compared to GranuFoam™. The Bio-Dome™ wound interface also effectively transmitted sufficient levels of fluid to the canister from simulated highly exuding wounds.

To better understand the physical performance attributes of wound interfaces, a range of in vitro physical testing and analytic studies using different levels of applied negative pressure were performed.

The analytic studies included finite element analysis (FEA) to predict strain forces applied to the wound bed; fluid handling testing to simulate exudate management capabilities; tensile strength of interface dressings to show their robustness during handling; and simulated bioadhesion testing.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
SolasCure publishes phase IIa clinical trial report in leading wound care journal